Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects

Imagem de Miniatura
Arquivos
art_COUTINHO_Brain_metabolism_and_cerebrospinal_fluid_biomarkers_profile_of_2015.PDF (770.48 KB)
Citações na Scopus
29
Tipo de produção
article
Data de publicação
2015
Editora
BIOMED CENTRAL LTD
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
FEITOSA, Esther A. A. F.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
ALZHEIMERS RESEARCH & THERAPY, v.7, article ID 58, 10p, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction: Mild cognitive impairment (MCI) is classically considered a transitional stage between normal aging and dementia. Non-amnestic MCI (naMCI) patients, however, typically demonstrate cognitive deficits other than memory decline. Furthermore, as a group, naMCI have a lower rate of an eventual dementia diagnosis as compared to amnestic subtypes of MCI (aMCI). Unfortunately, studies investigating biomarker profiles of naMCI are scarce. The study objective was to investigate the regional brain glucose metabolism (rBGM) with [F-18]FDG-PET and cerebrospinal fluid (CSF) biomarkers in subjects with naMCI as compared to a control group (CG) and aMCI subjects. Methods: Ninety-five patients were included in three different groups: naMCI (N = 32), aMCI (N = 33) and CG (N = 30). Patients underwent brain MRI and [F-18]FDG-PET. A subsample (naMCI = 26, aMCI = 28) also had an assessment of amyloid-beta, tau, and phosphorylated tau levels in the CSF. Results: Both MCI groups had lower rBGM in relation to the CG in the precuneus. Subjects with naMCI showed decreased right prefrontal metabolism as well as higher levels of CSF amyloid-beta relative to aMCI subjects. Conclusion: While amnestic MCI subjects showed a biomarker profile classically related to MCI due to Alzheimer's disease, naMCI patients illustrated a decrease in both prefrontal hypometabolism and higher CSF amyloid-beta levels relative to the aMCI group. These biomarker findings indicate that naMCI is probably a heterogeneous group with similar precuneus hypometabolism compared to aMCI, but additional frontal hypometabolism and less amyloid-beta deposition in the brain. Clinical follow-up and reappraisal of biomarkers of the naMCI group is needed to determine the outcome and probable etiological diagnosis.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/12407
Referências
  1. Alexopoulos P, 2013, J ALZHEIMERS DIS, V36, P401, DOI 10.3233/JAD-122329
  2. Jagust WJ, 2009, NEUROLOGY, V73, P1193, DOI 10.1212/WNL.0b013e3181bc010c
  3. Signorini M, 1999, NEUROIMAGE, V9, P63, DOI 10.1006/nimg.1998.0381
  4. Pachana NA, 2007, INT PSYCHOGERIATR, V19, P103, DOI 10.1017/S1041610206003504
  5. Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8
  6. Pike KE, 2007, BRAIN, V130, P2837, DOI 10.1093/brain/awm238
  7. Leech R, 2014, BRAIN, V137, P12, DOI 10.1093/brain/awt162
  8. Petersen RC, 2009, ARCH NEUROL-CHICAGO, V66, P1447, DOI 10.1001/archneurol.2009.266
  9. Petersen RC, 2011, NEW ENGL J MED, V364, P2227, DOI 10.1056/NEJMcp0910237
  10. Morbelli S, 2013, J NUCL MED, V54, P894, DOI 10.2967/jnumed.112.113928
  11. Li W, 2013, NEUROIMAGE, V78, P46, DOI 10.1016/j.neuroimage.2013.04.011
  12. Garibotto V, 2008, NEUROLOGY, V71, P1342, DOI 10.1212/01.wnl.0000327670.62378.c0
  13. Buckner RL, 2005, J NEUROSCI, V25, P7709, DOI 10.1523/JNEUROSCI.2177-05.2005
  14. Haldenwanger A, 2010, J ALZHEIMERS DIS, V22, P971, DOI 10.3233/JAD-2010-101203
  15. FAZEKAS F, 1987, AM J ROENTGENOL, V149, P351
  16. Mitchell AJ, 2009, ACTA PSYCHIAT SCAND, V119, P252, DOI 10.1111/j.1600-0447.2008.01326.x
  17. Mattsson N, 2009, JAMA-J AM MED ASSOC, V302, P385, DOI 10.1001/jama.2009.1064
  18. Hansson O, 2006, LANCET NEUROL, V5, P228, DOI 10.1016/S1474-4422(06)70355-6
  19. Murray ME, 2010, ARCH NEUROL-CHICAGO, V67, P1379, DOI 10.1001/archneurol.2010.280
  20. He J, 2009, ARCH NEUROL-CHICAGO, V66, P1393, DOI 10.1001/archneurol.2009.252
  21. Clark LR, 2013, J INT NEUROPSYCH SOC, V19, P635, DOI 10.1017/S1355617713000313
  22. Lancaster JL, 1997, HUM BRAIN MAPP, V5, P238, DOI 10.1002/(SICI)1097-0193(1997)5:4<238::AID-HBM6>3.0.CO;2-4
  23. Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303
  24. Gouw AA, 2011, J NEUROL NEUROSUR PS, V82, P126, DOI 10.1136/jnnp.2009.204685
  25. Szczepanski SM, 2014, NEURON, V83, P1002, DOI 10.1016/j.neuron.2014.08.011
  26. Jack CR, 2014, NEUROLOGY, V82, P1605, DOI 10.1212/WNL.0000000000000386
  27. Reed BR, 2004, ARCH NEUROL-CHICAGO, V61, P1545, DOI 10.1001/archneur.61.10.1545
  28. Fjell AM, 2014, PROG NEUROBIOL, V117, P20, DOI 10.1016/j.pneurobio.2014.02.004
  29. Jack CR, 2013, LANCET NEUROL, V12, P207, DOI 10.1016/S1474-4422(12)70291-0
  30. Buckner RL, 2012, NEUROIMAGE, V62, P1137, DOI 10.1016/j.neuroimage.2011.10.035
  31. Landau SM, 2011, NEUROBIOL AGING, V32, P1207, DOI 10.1016/j.neurobiolaging.2009.07.002
  32. Winblad B, 2004, J INTERN MED, V256, P240, DOI 10.1111/j.1365-2796.2004.01380.x
  33. Hedden T, 2013, NEUROLOGY, V80, P1341, DOI 10.1212/WNL.0b013e31828ab35d
  34. Brett M., 2002, NEUROIMAGE, V16, P2
  35. Brucki SMD, 2003, ARQ NEURO-PSIQUIAT, V61, P777, DOI 10.1590/S0004-282X2003000500014
  36. Cerami Chiara, 2015, Neuroimage Clin, V7, P187, DOI 10.1016/j.nicl.2014.12.004
  37. Clerici F, 2009, Q J NUCL MED MOL IM, V53, P646
  38. de Gobbi Porto FH, 2013, NEUROL INT, V5, pe16
  39. Drzezga A, 2003, EUR J NUCL MED MOL I, V30, P1104, DOI 10.1007/s00259-003-1194-1
  40. Espinosa A, 2013, J ALZHEIMERS DIS, V34, P769, DOI 10.3233/JAD-122002
  41. FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
  42. Han JW, 2012, ALZHEIMERS DEMENT, V8, P553, DOI 10.1016/j.jalz.2011.08.007
  43. Jack CR, 2013, NEUROLOGY, V81, P1732, DOI 10.1212/01.wnl.0000435556.21319.e4
  44. Johnson KA, 2007, J NEUROL NEUROSUR PS, V78, P240, DOI 10.1136/jnnp.2006.096800
  45. Nitrini R., 2007, DEMENTIA NEUROPSYCHO, V1, P32
  46. Nobili F, 2008, J NEUROL, V255, P1344, DOI 10.1007/s00415-008-0897-4
  47. Pa J, 2009, ANN NEUROL, V65, P414, DOI 10.1002/ana.21591
  48. Pfeffer RI, 1982, GERONTOLOGY, V37, P323, DOI 10.1093/GER0NJ/37.3.323
  49. Rabinovici Gil D, 2015, Continuum (Minneap Minn), V21, P646, DOI 10.1212/01.CON.0000466658.05156.54
  50. SHEIKH J I, 1986, Clinical Gerontologist, V5, P165
  51. SUNDERLAND T, 1989, J AM GERIATR SOC, V37, P725
  52. Takada LT, 2006, ARQ NEURO-PSIQUIAT, V64, P35, DOI 10.1590/S0004-282X2006000100008
  53. Tatsuoka C, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt168
  54. Woodward M, 2010, INT PSYCHOGERIATR, V22, P1280, DOI 10.1017/S1041610210001596

Coleções
Artigos e Materiais de Revistas Científicas - FM/MNE
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/15
Carregar mais